Famciclovir 250mg tablets
Requires a prescription from a doctor or prescriber
Famciclovir, marketed as Famvir by Novartis, is a guanine analogue used to treat herpes virus infections.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Famciclovir
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Famciclovir
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
30 branded products available
MHRA licensed products
View all licensed products for Famciclovir on the MHRA register
Famvir 250mg tablets
Famvir 250mg tablets
Famciclovir 250mg tablets
Famciclovir 250mg tablets
Famciclovir 250mg tablets
Famciclovir 250mg tablets
Famciclovir 250mg tablets
Famciclovir 250mg tablets
Famciclovir 250mg tablets
Famciclovir 250mg tablets
Famciclovir 250mg tablets
Famciclovir 250mg tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
750 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 6 · Randomised trials: 14 · 1989–2025
Showing the 50 most relevant studies, sorted by most relevant.
S. Tyring, R. Barbarash, J. Nahlik, et al.
Annals of Internal Medicine, 1995
S. Tyring, K. Beutner, B.A. Tucker, et al.
Archives of family medicine, 2000
S. Sacks, F. Aoki, Franciso Diaz-Mitoma, et al.
JAMA, 1996
Mancini A, Inchingolo AM, Marinelli G, et al.
2025
- Herpes Simplex
- Stomatitis, Herpetic
- Antiviral Agents
Herpes Simplex Virus (HSV) infections, caused primarily by HSV-1 and HSV-2, are among the most prevalent viral diseases worldwide, with recurrent manifestations that significantly affect quality of life. Therapeutic strategies include both topical and systemic interventions, each with distinct goals. This systematic review was conducted according to PRISMA guidelines. A comprehensive search of PubMed, Scopus, and Web of Science (2005-2025) identified studies evaluating topical or systemic treatments for HSV. Eligible studies included randomized controlled trials and observational studies reporting validated clinical outcomes. Topical treatments, including acyclovir cream, docosanol, and newer formulations, primarily reduce lesion duration and alleviate local symptoms when applied early. These interventions have limited systemic absorption and generally do not influence recurrence frequency. Novel delivery methods and combination strategies, such as acyclovir-hydrocortisone formulations or photodynamic therapy, may enhance local efficacy and symptom control. Systemic Therapies: Systemic antivirals, such as acyclovir, valacyclovir, and famciclovir, target both lesion resolution and recurrence prevention. Evidence from randomized trials supports their use for episodic and suppressive therapy, including short-course, high-dose regimens that improve adherence while controlling symptoms. Systemic therapy is particularly indicated for recurrent, disseminated, or high-risk infections. Topical and systemic therapies serve complementary roles in HSV management. Topical agents are useful for localized or initial episodes, while systemic therapy addresses broader clinical objectives, including recurrence reduction. Future research should focus on mechanism-based therapies, novel delivery systems, and standardized outcome measures to guide personalized treatment strategies. Emerging therapies targeting viral latency, immune modulation, and gene-editing technologies hold promise for long-term suppression and personalized management of HSV infections.
Abstract licence: CC BY
F. Diaz-Mitoma, R. Sibbald, S. Shafran, et al.
JAMA, 1998
R. Dworkin, E. Nagasako, Robert W Johnson, et al.
Pain, 2001
R. Hodge
Antiviral Chemistry and Chemotherapy, 1993
F. Aoki, S. Tyring, F. Diaz-Mitoma, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006
F. Peng, H He, Tianbao Xia, et al.
Infection and Drug Resistance, 2023
Vernau KM, Kim S, Thomasy SM, et al.
2024
- Respiratory Tract Infections
- Cat Diseases
- Doxycycline
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
10 hours
Mechanism
Famciclovir undergoes rapid biotransformation to the active antiviral compound p…
Food interactions
1 warning
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
77 %
Half-life
10 hours
Protein binding
20-25%
Volume of distribution
0.17 L/kg
Metabolism
Elimination
Clearance
6.3 L/h
* 0.48 +/- 0.09 L/hr/kg [healthy male]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 14 of 14 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
* 0.48 +/- 0.09 L/hr/kg [healthy male]
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC J05AB09
ATC S01AD07
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Famciclovir
Additional database identifiers
Drugs Product Database (DPD)
156
ChemSpider
3207
BindingDB
50248001
ZINC
ZINC000001530635
GenBank Gene Database
X14112
GenBank Protein Database
59530
UniProt Accession
DPOL_HHV11
HUGO Gene Nomenclature Committee (HGNC)
HGNC:553
GeneCards
AOX1
GenBank Gene Database
L11005
GenBank Protein Database
438656
Guide to Pharmacology
3186
UniProt Accession
AOXA_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q420186), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.